the management seem to be revenue driven, especillay George,...

First 8 Last

mackum8

1,077 Posts.

06/03/19

02:08

Post #: 37664891

Originally posted by DrKnow: ↑
very simple - sales revenues

what seperates companies at the moment in MC / Hemp / CBD space is talking versus delivering revenues and EXL has delivered revenues

Their international comparison companies (charloettes web and CV Science ) have markets caps multiples well higher than their compaitive sales figures - so EXL caught up

Here is my numbers, I focus on revenues not income as this is a land grab market at the moment so brand building, advertising spend and revenue growth are the key factors to success in my opinion

THESE NUMBERS ARE MAYBE A few weeks out of date but the picture is clear:

ASX Code Company Mkt Cap Ratio (mkt cap / revenue) 03/2019 Quarterly Revenue from 4C 12/2018 09/2018
1 AGH ALTHEA 23.4 28.5
$82 $28
2 BDA BOD AUSTRALIA 45.0 5.9
$766 $141
3 ZLD ZELDA THERAPEUTICS 41.0

$0 $0
4 MXC MGC PHARMA 49.0 6.6
$744 $135
5 CPH CRESO PHARMA 55.0 25.1
$219 $170
6 MDC MEDLAB CLINICAL 87.0 6.9
$1,269 $1,222
7 AC8 AUSCANN 188.0

$0 $0
8 CAN CANN GROUP 297.0

$1 $2
9 EXL ELIXINOL 445.0 3.9
$11,334 $9,831
10

$14,415 $11,529
Expand
the management seem to be revenue driven, especillay George, they will not be afraid to take on products to drive revenue, so I’m pretty confident we will see a substantial growth this year.

BDA Price at posting: 43.5¢ Sentiment: Buy Disclosure: Held

3 Upvote

0 Great analysis

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

AXP

Tambourah chases gold veins and mineralisation extension with drilling

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

There are more pages in this discussion • 4 more messages in this thread...

First 8 Last

Add BDA (ASX) to my watchlist

	ASX Code	Company	Mkt Cap	Ratio (mkt cap / revenue)	03/2019	Quarterly Revenue from 4C 12/2018	09/2018
1	AGH	ALTHEA	23.4	28.5		$82	$28
2	BDA	BOD AUSTRALIA	45.0	5.9		$766	$141
3	ZLD	ZELDA THERAPEUTICS	41.0			$0	$0
4	MXC	MGC PHARMA	49.0	6.6		$744	$135
5	CPH	CRESO PHARMA	55.0	25.1		$219	$170
6	MDC	MEDLAB CLINICAL	87.0	6.9		$1,269	$1,222
7	AC8	AUSCANN	188.0			$0	$0
8	CAN	CANN GROUP	297.0			$1	$2
9	EXL	ELIXINOL	445.0	3.9		$11,334	$9,831
10						$14,415	$11,529

the management seem to be revenue driven, especillay George,...

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Tambourah chases gold veins and mineralisation extension with drilling

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Featured News